Share
Lymphoma Hub
What is the clinical significance of the long-term results from the EPCORE NHL-2 trial of epcoritamab + R-CHOP for previously untreated high-risk DLBCL?
•
During the 18th International Conference on Malignant Lymphomas (ICML), Jun 17–21, 2025, Lugano, CH, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. We asked about the clinical significance of the long-term results from the EPCORE NHL-2 (NCT04663347) trial, which evaluated epcoritamab (epcor) in combination with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) in patients with B-cell non-Hodgkin lymphoma.
During this interview, Dr Joshua Brody discussed the latest data presented at the 18th ICML 2025 from the EPCORE NHL-2 study, with a focus on the cohort of patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with epcor + R-CHOP as frontline therapy. Brody highlighted the significance of durable remission in this difficult-to-treat population, provided an overview of the top-line data from the trial, and discussed upcoming developments, including the phase III randomized EPCORE DLBCL-2 (NCT05578976) trial, which is currently underway and will further evaluate the efficacy and safety of adding epcor to standard R-CHOP in this high-risk patient population.
This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
More episodes
View all episodes
ASH 2025 | Key highlights in lymphoma and CLL
07:14|During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Brody discussed the key highlights in lymphoma and chronic lymphocytic leukemia (CLL) from the meeting. Brody highlights several presentations on approved and novel immunotherapies for patients with lymphoma and CLL. He discusses the significant progress made in the treatment of B-cell non-Hodgkin lymphoma (NHL). He also discusses the historically poor outcomes in patients with T-cell lymphoma and highlights some of the novel therapies presented at ASH for this patient population.ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL
04:10|During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What are the latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL?
07:29|The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with chronic lymphocytic leukemia (CLL)?This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL
06:37|During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What do the primary results from the EPCORE FL-1 trial tell us about epcoritamab + R2 vs R2 alone in patients with R/R FL?In this interview, Falchi highlights that epcoritamab and R2 do not have overlapping toxicities and that the combination may offer synergistic activity. He concludes that epcoritamab sets a new benchmark as a readily available treatment for patients with R/R FL.This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
04:49|During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).In this interview, Abdulhaq discusses 3-year follow-up results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs rituximab (R)-GemOx in patients with R/R DLBCL who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT). They also discuss the efficacy and safety of Glofit-GemOx in clinically relevant patient subgroups.This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity
02:53|During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR. We asked, What does the latest analysis of the EPCORE NHL-6 trial tell us about the efficacy and safety of bispecific antibodies in an ethnically and racially diverse patient population? In this interview, Torres highlights how the findings from the EPCORE NHL-6 trial support the safe and efficacious administration of subcutaneous epcoritamab in the outpatient setting in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and discusses efficacy and safety findings in an ethnically and racially diverse group of patients.This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
36:21|During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The discussion was preceded by a presentation by Gareth Gregory, chaired by Gilles Salles, and featured Ulrich Jäger, Francesc Bosch, Michael Dickinson, Astrid Pavlovsky, Marek Trněný, Alison Moskowitz, and Stefano Luminari. Gregory presented an overview of the STARGLO trial, efficacy and safety data, and key takeaways. This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.What factors influence BTKi + BCL-2i treatment selection for patients with CLL?
07:04|The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.Latest updates from the phase III STARGLO trial: 2L and 3L+ data
03:55|The Lymphoma Hub was pleased to speak to Charles Herbaux, University of Montpellier, FR. Herbaux discussed the latest updates from the phase III STARGLO trial (NCT04408638), with a focus on second-line (2L) and third-line+ (3L+) data. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence on the content of this resource.